These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29735753)

  • 1. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.
    Jin Y; Borell H; Gardin A; Ufer M; Huth F; Camenisch G
    Eur J Clin Pharmacol; 2018 Apr; 74(4):455-464. PubMed ID: 29273968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.
    Gardin A; Gray C; Neelakantham S; Huth F; Davidson AM; Dumitras S; Legangneux E; Shakeri-Nejad K
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1593-1604. PubMed ID: 30105453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.
    Gardin A; Ufer M; Legangneux E; Rossato G; Jin Y; Su Z; Pal P; Li W; Shakeri-Nejad K
    Clin Pharmacokinet; 2019 Mar; 58(3):349-361. PubMed ID: 30088221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.
    Walles M; Wolf T; Jin Y; Ritzau M; Leuthold LA; Krauser J; Gschwind HP; Carcache D; Kittelmann M; Ocwieja M; Ufer M; Woessner R; Chakraborty A; Swart P
    Drug Metab Dispos; 2013 Sep; 41(9):1626-41. PubMed ID: 23775850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
    Gardin A; Shakeri-Nejad K; Feller A; Huth F; Neelakantham S; Dumitras S
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1565-1574. PubMed ID: 31392364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects.
    Prakash C; Johnson KA; Gardner MJ
    Drug Metab Dispos; 2008 Jul; 36(7):1218-26. PubMed ID: 18372400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
    Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Gardin A; Zaehringer A; Dodman A; Su Z; Legangneux E
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):41-53. PubMed ID: 27443658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations.
    Huth F; Gardin A; Umehara K; He H
    Clin Pharmacol Ther; 2019 Nov; 106(5):1113-1124. PubMed ID: 31199498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.
    Beers JL; Fu D; Jackson KD
    Drug Metab Dispos; 2021 Oct; 49(10):882-891. PubMed ID: 34330718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative Metabolism.
    Lee CA; Oh DA; Tang Y; Yi P; Bashir M; English S; Croft M; Blackburn A; Bloom S; Gilder K; Grundy JS
    Clin Pharmacol Drug Dev; 2023 Jun; 12(6):553-571. PubMed ID: 37132407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.